SUMMARY An experimental model of cirrhosis was developed in the rat to assess the effect of disease and pharmacological manipulation on blood flow, shunting and portal pressure. With progression in the severity of histological cirrhosis there was a steady fall in effective liver blood flow as measured with radioisotope labelled colloid. This corresponded to a rise in portal pressure and shunting with a close correlation between the two (r=0-7, p<0-01). In control animals and when portal hypertension was caused by extrahepatic obstruction, beta-blockade with propranolol, but not selective beta 2 blockade, significantly decreased liver blood flow. With cirrhosis there was a variable response to propranolol depending on the histological severity of disease, the height of portal pressure and degree of shunting. There is a possibility therefore that a potential may exist for lowering portal pressure by manipulating intrahepatic shunting.
Considerable enthusiasm exists for attempting pharmacological reduction of raised portal venous pressure in patients with cirrhosis and portal hypertension. The rationale for this therapeutic approach being that by a lowering of such pressure the risk of variceal bleeding, and hence life threatening complications, may become less without the additional problems that arise with therapeutic surgical shunting. Most attention has been concentrated on the effects of beta adrenergic blockade' with initial studies using propranolol.'I3
The mechanisms whereby pressure may be reduced by such drug therapy and the effects which this could have on the functional blood flow of the liver is, however, still far from clear. ' The major local haemodynamic factors involved in the pathophysiological equation of cirrhosis are the portal venous pressure itself, the dual nature of the hepatic arterial and portal venous blood supply, together with the extent of any intra or extra hepatic shunting.
The aims of the present study were to evaluate the relationship of these parameters with the development of cirrhosis in an experimental animal model. In addition an assessment was made of acute changes in hepatic blood flow as a result of drug therapy with both propranolol (a non-specific betablocker) and B2 118551 (a beta 2-blocker). studies.'3 The microspheres were agitated for two minutes using a whirlimixer and approximately 0.05 ml drawn into a graduated 1 ml syringe. This was then connected to the portex tubing and the contained microspheres injected over 10 seconds, followed by 0-2 ml. normal saline over 20 seconds to flush the tube. After 20 minutes the rat was killed by exsangination via an aortic puncture. The lungs and liver once weighed were subsequently counted in a J and P Nucleonics gamma scintillation counter.
Methods
The percentage of portal systemic shunting was then calculated using a simple equation which provides a relative index, thereby obviating the need to measure precise quantities of microspheres/ radioactivity injected: % PSS=net lung radioactivity/net (lung+liver) radioactivity x 100.
DRUGS
Based on a careful assessment of the relevant pharmacodynamics and pharmacokinetics the route Changes in bloodflow, portalpressure and shunting during the development ofcirrhosis of administration chosen for propranolol and by inference B2 118551 was oral. Similarly the most appropriate dose to produce a pharmacological effect was selected which in the case of propranolol was confirmed experimentally by demonstrating a significant reduction in heart rate. STATISTICAL 
ANALYSIS
Data have been presented as means ± SEM. Statistical comparisons have been made using a standard Student's t test. With repeat blood flow measurement a difference of >10% was considered significant as this was in excess of any error intrinsic consequent on the technique of blood flow measurement used.
Results
There were 26 rats with grade I cirrhosis, 34 with grade II, and 36 with grade III. There were 13 rats with extrahepatic portal hypertension. In the group of rats with cirrhosis 36 underwent blood flow studies before and after propanolol.
BIOCHEMICAL CHANGES (TABLE 1) There were no significant differences in the biochemical tests between those control rats who had or had not received previous enzyme induction. There were consistent changes in the biochemical parameters used to assess disease severity matching the grading system based on histology alone. PORTAL PRESSURE (TABLE 2) The mean portal pressure in the control rats was 9 cm saline. With cirrhosis there was an increase in the (TABLE 2) With progressively severe cirrhosis there was a steady fall in the recorded liver blood flow from a mean of 1-26 ml/g/min in control rats to 0-48 ml/g/min in grade III. Overall there was a poor negative correlation between increased portal pressure and a reduction in blood flow (r=-0-04 with p<0.05). There was no correlation between the degree of shunting and any blood flow changes.
EFFECT OF BETA BLOCKADE (TABLES 3 AND 4) In the control rats propranolol resulted in a statistically significant fall in blood flow. There was a small reduction produced by beta 2 blockade alone using B2 118551 but this did not reach statistical significance.
In cirrhotic rats propranolol produced an increased measured flow of greater than 10% in 20 rats with a decreased flow of greater than 10% in 16 rats.
There were highly significant differences in the disease severity, level of portal pressure and degree of shunting in these two groups of cirrhotic rats.
Discussion
Within the limits of the experimental techniques used the majority of portal systemic shunting measured after the portal injection of microspheres in the cirrhotic rats was intrahepatic. This conclusion arises from the comparative values of shunting in the extrahepatic portal hypertensive rats without liver damage whose portal pressures were raised to very similar levels. A close correlation might be anticipated between the level of portal pressure and the degree of extrahepatic portal systemic shunting but the demonstration of a good correlation between such pressure and intrahepatic venous shunting introduces an interesting question with regard to the pathogenesis of the latter. The presence of intrahepatic venous shunts from portal vein to both central and other portal tributaries are considered to arise from both bridging fibrosis and the loss of cell plate alignment as repair runs parallel with necrosis in the cirrhotic process.'4 Although showing a good correlation for the overall group of rats with cirrhosis the data shown as a summary in Table 2 indicate that the significant rise in portal pressure and shunting occurs between grade I and grade II cirrhosis. In grade III there is no further increase in the level of portal pressure but, although not statistically significant, there was a trend towards a further increase in shunting. If it is accepted that the majority of shunting measured was intrahepatic then this suggests portal pressure acts as a stimulus to divert more blood through these potentials pathways.
Similarly, as an extension of this argument, it is conceivable that by manipulating intrahepatic shunting an effect on portal pressure could be produced. The progressive fall in measured blood flow using radio-labelled colloid relates to several factors." In addition to reflecting any actual changes in flow there are certain aspects which must be considered when interpreting results. The technique relies on the extraction/isolation of colloid by the Kupffer cells lining the liver sinusoids. To reflect vascular flow, blood laden with colloid must perfuse sinusoids. These in turn need to be lined by functioning Kupffer cells. The liver receives a dual blood supply with the relative proportions of arterial and venous components altering as disease progresses and intrahepatic shunts develop within both territories."4 Blood flowing through such shunts will fail to perfuse sinusoids and therefore avoid exposure to Kupffer cells. In addition to this reduction in functional intrahepatic perfusion there is a redistribution of colloid uptake; principally to the spleen and other potential reticuloendothelial sites such as the bone marrow. This arises as a consequence of any qualitative or quantitative impairment to Kupffer cells and the presence of an actual increase in functional splenic activity. The lack of correlation between one type of shunting and blood flow changes reflects these various factors.
When giving adrenoreceptor blocking drugs to patients with raised portal pressure most authors attribute any fall in this pressure to a reduction of cardiac output through beta-i-blockade and splanchnic flow as a sequel to beta-2-blockade;'15 with changes to liver blood flow being secondary phenomena. The question of specific intra-hepatic effect has, however, received little attention. In this study there may be evidence to support such a possibility. In those rats with histologically more severe cirrhosis, higher portal pressures and increased shunting the administration of propranolol led to an increased functional perfusion of sinusoids. This could have arisen because either more blood was actually exposed to Kupffer cells, the same amount was exposed for a longer time or there was an increase in reticuloendothelial extraction efficiency. This latter possibility would seem unlikely as no direct effect of beta-blockade on Kupffer cells has been shown.
The data from control rats suggest that the reduction in measured liver blood flow was predominantly caused by beta-i-blockade; the effect of beta-2-blockade alone being insufficient to bring about significant reductions. In those cirrhotic rats with higher pressures and shunting the resistance to portal venous flow would also be higher, together with a greater arterial component flow. A reduction of cardiac output will reduce the hepatic arterial pressure. Hepatic arterial vasodilation, already near maximal, is mediated by beta-2-receptors. A blockade of the latter combined with the reduced cardiac output would have the reciprocal effect of reducing portal venous resistance, hence pressure. This would reduce intrahepatic portal systemic shunting and lead to increased perfusion of sinusoids. Although the sum total of volume input to the liver via the hepatic artery and portal vein may be reduced, the functional sinusoidal perfusion measured using Technecoll may actually increase.
The implications if such a mechanism exists are two-fold. Firstly there may not be an anticipated deleterious effect on functional liver blood flow using beta-blockers. More importantly, though, the potential may well be present to manipulate intrahepatic shunting and hence reduce portal pressure with other drugs such as vasodilators.
